Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]
Naseem A +3 more
europepmc +1 more source
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy. [PDF]
Wang Y +55 more
europepmc +1 more source
Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]
Kittai AS +6 more
europepmc +1 more source
Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease. [PDF]
Ziouti F +8 more
europepmc +1 more source
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. [PDF]
Wang X +14 more
europepmc +1 more source
Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers. [PDF]
Kluitmans DJF +8 more
europepmc +1 more source
The Bruton tyrosine kinase inhibitor acalabrutinib aborts ongoing acute food-induced anaphylactic reactions in humanized mice. [PDF]
Arce B +10 more
europepmc +1 more source
Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. [PDF]
Goodale EC +13 more
europepmc +1 more source
Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures. [PDF]
Darragh AC +5 more
europepmc +1 more source

